Information For Healthcare Professionals

Notice: Mpox illness, including severe infections, continue to occur across the United States. CDC urges clinicians to consider mpox when lesions consistent with mpox are observed in a patient, even if an alternate etiology (e.g., herpes simplex virus, syphilis) is considered more likely. Consult public health authorities for access to mpox therapeutics when appropriate. Treatment with tecovirimat can be considered via the NIH sponsored STOMP trial. Tecovirimat use under the expanded access Investigational New Drug protocol must be for patients who meet eligibility criteria and per the recommended dosing.

Administration of more than 2 doses of JYNNEOS vaccine (“boosters”) is currently not recommended except for certain people who work with orthopoxviruses in research or mpox diagnostic laboratories. Encourage your patients with risk factors who have not previously had mpox to get both recommended doses and to continue to reduce their risk of getting mpox whether or not they’ve been fully vaccinated. Read more about why boosters aren’t currently recommended and why people who recovered from mpox do not need to be vaccinated.